1.
Malnique F, Garcia T de A, Ferreira DM, et al. USE OF DAPAGLIFLOZIN (FORXIGA) IN THE MANAGEMENT OF OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES. Editora. Published online November 18, 2025:368-379. Accessed November 21, 2025. https://sevenpubl.com.br/editora/article/view/8517